• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

What Does Multiple Myeloma Mean?

by MM360 Staff | Aug 23, 2025 | Uncategorized

Source: CureToday articles Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Read More

FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma

by MM360 Staff | Aug 21, 2025 | Uncategorized

Source: CureToday articles The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form. Read More

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

by MM360 Staff | Aug 20, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds

by MM360 Staff | Aug 20, 2025 | Myeloma News

Source: Pharmacy Times articles New research uncovers the complex tumor microenvironment in multiple myeloma, revealing unique plasma cell ecosystems that challenge existing treatment approaches. Read More

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

by MM360 Staff | Aug 19, 2025 | Publications

Haematologica. 2025 Aug 14. doi: 10.3324/haematol.2025.288174. Online ahead of print. ABSTRACT Not available. PMID:40820831 | DOI:10.3324/haematol.2025.288174
« Older Entries
Next Entries »

Recent Content

  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
  • Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
  • Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
  • (no title)
  • FDA OK’s belantamab mafodotin-blmf for multiple myeloma
  • Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT